Treatment of Attention Deficit Hyperactivity Disorder in Children and Adolescents: Safety Considerations

Author： Wolraich Mark L. McGuinn Laura Doffing Melissa

ISSN： 0114-5916

Source： Drug Safety, Vol.30, Iss.1, 2007-01, pp. : 17-26

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacological Management of Attention-Deficit Hyperactivity Disorder in Adolescents: Special Considerations

By Hazell Philip

CNS Drugs, Vol. 21, Iss. 1, 2007-01 ,pp. : 37-46

Adis International

Access to resources Recommend Favorite

Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents—meta-analysis and meta-regression analysis

By Cheng Jackie Chen Ronald Ko John Ng Emil

Psychopharmacology, Vol. 194, Iss. 2, 2007-10 ,pp. : 197-209

Springer Publishing Company

Access to resources Recommend Favorite

Comorbid Attention Deficit/Hyperactivity Disorder and Substance Use Disorder: Treatment Considerations

Current Drug Abuse Reviews, Vol. 5, Iss. 3, 2012-09 ,pp. : 190-198

Bentham Science Publishers

Access to resources Recommend Favorite

Spotlight on Methylphenidate Controlled-Delivery Capsules (Equasym™XL, Metadate CD™) in the Treatment of Children and Adolescents with Attention-Deficit Hyperactivity Disorder

By Anderson Vanessa R. Keating Gillian M.

CNS Drugs, Vol. 21, Iss. 2, 2007-01 ,pp. : 173-175

Adis International

Access to resources Recommend Favorite

Spotlight on Atomoxetine in Attention-Deficit Hyperactivity Disorder in Children and Adolescents†

By Garnock-Jones Karly P. Keating Gillian M.

CNS Drugs, Vol. 24, Iss. 1, 2010-01 ,pp. : 85-88

Adis International

Access to resources Recommend Favorite